信達生物(01801.HK)商業化產品「耐立克」於中國獲批
信達生物(01801.HK)公布,由亞盛醫藥(06855.HK)開發的原創1類新藥奧雷巴替尼片「耐立克」(研發代號:IBI-348)正式獲得中國藥監局批准用於治療任何酪氨酸激(酉每)抑制劑耐藥,並採用經充分驗證的檢測方法診斷為伴有T315I突變的慢性期或加速期成人慢性髓細胞白血病患者。
公司今年7月與亞盛醫藥達成在中國市場就耐立克共同開發和共同商業化推廣的戰略合作。公司表示,相關產品為公司所獲批的第六款產品,亦是第二款獲批的小分子產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.